Clinical Trial Update: Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the impact of irbesartan on biochemical and functional markers of endothelial dysfunction in hypertension patients; the study has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• AVAPRO (irbesartan)

Snippet

Sponsor: Sanofi | Conditions: Hypertension | Phase 4 | Status: COMPLETED